China Vector-Borne Disease Diagnostics Market Size & Growth Rate
According to 6Wresearch internal database and industry insights, the China Vector-Borne Disease Diagnostics Market was valued at USD 399.0 million in 2025 and is projected to reach USD 607.92 million by 2032, growing at a CAGR of approximately 6.2% during 2026–2032.
China Vector-Borne Disease Diagnostics Market Highlights
| Report Metric | Details |
| Report Name | China Vector-Borne Disease Diagnostics Market |
| Market Size 2025 | USD 399.0 million |
| Market Size 2032 | USD 607.92 million |
| Absolute Growth 2025–2032 | USD 208.92 million |
| CAGR 2026–2032 | 6.2% |
| Peak Annual Growth | 8.7% in 2026 |
| Forecast Period | 2026–2032 |
| Historical Data | 2022–2025 |
| Base Year | 2025 |
| Leading Disease Type, 2025 | Malaria (46% share) |
| Leading Test Type, 2025 | Rapid Diagnostic Test (50% share) |
| Leading Sample Type, 2025 | Blood (39% share) |
| Leading End User, 2025 | Hospitals (41% share) |
| Fastest-Growing Disease Type | Dengue (8.0% CAGR) |
| Fastest-Growing Test Type | PCR/ELISA (8.3% CAGR) |
| Fastest-Growing Sample Type | Serum/Plasma (7.4% CAGR) |
| Fastest-Growing End User | Primary Health Clinics (8.5% CAGR) |
| Growing Sector | Primary Health Clinics |
| Key End Users | Hospitals, Primary Health Clinics, Pathology Labs, Travel Clinics |
China Vector-Borne Disease Diagnostics Market Year-wise Growth Rate and Key Drivers (2022–2032)
This graph illustrates the annual growth rates of the market from 2022 to 2032, highlighting a steady upward trajectory and projected market expansion over the forecast period.
Below, each year's estimated growth is shown next to the factor that most influenced it.
| Year | Estimated Annual Growth (%) | Market Rationale |
| 2022 | 4.1 | The market experienced steady growth due to ongoing disease surveillance efforts from the Chinese Center for Disease Control and Prevention. |
| 2023 | 5.8 | Increased malaria cases led to heightened demand for diagnostics across healthcare facilities, particularly in urban areas. |
| 2024 | 7.1 | The rise in dengue cases further accelerated the need for effective testing solutions in major cities. |
| 2025 | 4.3 | Growth slowed as the market adjusted to previous high demand levels following extensive testing initiatives. |
| 2026 | 8.7 | The launch of the 'Vector-Borne Disease Control Program' is expected to boost market growth through improved diagnostics. |
| 2027 | 3.8 | A slowdown is projected as the market stabilises after peak investments in diagnostic technologies. |
| 2028 | 4.8 | Demand is expected to increase again due to rising awareness of vector-borne diseases among healthcare providers. |
| 2029 | 5.8 | Healthcare facilities are projected to expand testing capabilities, driving further growth in urban health clinics. |
| 2030 | 7.9 | The government's focus on improving diagnostic access is expected to spur market activity in rural areas. |
| 2031 | 5.3 | Growth is projected to slow as the market begins to stabilise after rapid expansions in diagnostic infrastructure. |
| 2032 | 7.2 | Increased investments in diagnostic technologies are expected to improve market performance and accessibility. |
Note: Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary forecasting methodology, utilizing the latest available industry data, government publications, and primary research inputs.
China Vector-Borne Disease Diagnostics Market Synopsis
Vector-Borne Disease Diagnostics in China encompasses testing methods for diseases transmitted by vectors such as mosquitoes and ticks. These diagnostics, including PCR and rapid tests, are crucial for identifying infections like malaria and dengue. The China Vector-Borne Disease Diagnostics Market is growing due to an increase in disease incidence and a robust public health infrastructure. In 2021, over 20,000 malaria cases were reported, underscoring the urgent need for effective diagnostics. Government initiatives, such as the 'Vector-Borne Disease Control Program', are propelling market growth by improving testing capabilities.
Market Dynamics Impact Analysis (2026–2032)
| Factor | Type | Impact | Primary Segment Affected |
| Increased malaria cases drive demand for timely diagnostics. | Driver | High | Malaria |
| The prevalence of dengue outbreaks boosts testing needs. | Driver | High | Dengue |
| The growing urban population creates a need for accessible diagnostics. | Opportunity | High | Primary Health Clinics |
| Investments in rapid diagnostic tests present a market gap. | Opportunity | High | Rapid Diagnostic Test |
| Limited rural healthcare access restricts diagnostic availability. | Restraint | High | PCR/ELISA |
| High costs of advanced testing technologies hinder adoption. | Restraint | Medium | PCR/ELISA |
| Vector-Borne Disease Diagnostics in China faces regulatory hurdles. | Challenge | High | Malaria |
| Competition from alternative diagnostic methods poses risks. | Challenge | Medium | Malaria |
Evaluation of Drivers in China Vector-Borne Disease Diagnostics Market (2026–2032)
Below mentioned are some major drivers and their influence on market dynamics.
| Drivers | Primary Segment Affected | Why It Matters (Evidence) |
| Rising malaria cases increase demand for diagnostics. | Malaria | In 2021, over 20,000 malaria cases highlighted the need for effective testing across healthcare facilities. |
| Dengue outbreaks necessitate accurate testing solutions. | Dengue | PCR testing is the gold standard for confirming dengue infections in major cities, ensuring timely treatment. |
| Urban healthcare facilities expand testing capabilities. | Primary Health Clinics | Approximately 70% of hospitals in urban areas are equipped with PCR testing, improving diagnostic access. |
| Government initiatives improve disease surveillance. | Malaria | The 'Vector-Borne Disease Control Program' aims to improve diagnostics and monitoring for vector-borne diseases. |
| Increased public health awareness drives testing. | Malaria | Public awareness campaigns regarding vector-borne diseases are emphasised to encourage timely testing. |
Growth in the Vector-Borne Disease Diagnostics market in China comes from rising malaria cases, increased dengue outbreaks, and urban healthcare facility expansions. In 2021, over 20,000 malaria cases underscored the urgent need for effective diagnostics, prompting healthcare providers to invest in testing capabilities. The gold standard PCR tests for dengue are widely adopted in major cities, ensuring accurate detection and timely treatment. Urban hospitals are now equipped with PCR testing, improving access to diagnostics for patients.
Evaluation of Restraints in China Vector-Borne Disease Diagnostics Market
The following restraints limit how fast demand can grow.
| Market Restraint | Primary Segment Affected | Why It Matters (Evidence) |
| Limited rural healthcare access restricts diagnostic availability. | PCR/ELISA | Many rural areas lack adequate facilities for advanced testing, affecting patient outcomes and timely diagnosis. |
| High costs of advanced testing technologies hinder adoption. | PCR/ELISA | The expenses associated with PCR testing can deter healthcare facilities from investing in necessary equipment. |
| Regulatory hurdles delay the introduction of new diagnostic methods. | Malaria | Compliance with stringent regulations can slow down the market entry of innovations in diagnostics. |
| Competition from alternative diagnostic methods poses risks. | Malaria | Emerging technologies may divert attention from established diagnostic practices, impacting market share. |
| Limited awareness of vector-borne diseases in some regions. | Malaria | Inadequate public knowledge can reduce demand for necessary diagnostic services and hinder disease management. |
China Vector-Borne Disease Diagnostics Market Challenges
The China Vector-Borne Disease Diagnostics market faces regulatory hurdles that delay the approval of new testing methods, impacting timely access for healthcare providers. Skills shortages in rural areas limit the number of trained personnel available to administer and interpret diagnostics, which affects patient care in these regions. Buyers in urban health facilities encounter high costs associated with maintaining advanced PCR testing equipment, often exceeding 1 million yuan per unit. Technology gaps persist as many local laboratories lack modern diagnostic tools, leading to reliance on outdated methods that compromise accuracy and reliability for patients.
Trends in the China Vector-Borne Disease Diagnostics Market
Below mentioned are some of the trends shaping the China Vector-Borne Disease Diagnostics Market growth.
- Launch of 'Vector-Borne Disease Control Program': In 2023, the National Health Commission initiated this program with a budget of 500 million yuan to improve diagnostics and surveillance for vector-borne diseases, boosting testing capabilities across the country.
- Shift towards Rapid Diagnostic Tests: Since 2021, there has been a marked increase in the use of Rapid Diagnostic Tests, accounting for about 60% of malaria diagnostics in primary health settings, streamlining patient care and improving response times.
- Increased focus on urban healthcare facilities: The rise in urban population has led to greater investments in primary health clinics, which are now equipped with rapid diagnostic tests for immediate patient care, improving access to necessary diagnostics.
- Growth of PCR Testing in Major Cities: Since 2022, approximately 70% of hospitals in urban areas have adopted PCR testing for vector-borne diseases, ensuring accurate and timely diagnosis for patients, improving overall healthcare outcomes.
Investment Opportunities in the China Vector-Borne Disease Diagnostics Market
Below are the investment opportunities with the strongest case in the China Vector-Borne Disease Diagnostics Market.
- 500 million yuan allocated for disease control: The recent budget allocation by the National Health Commission presents an opportunity to improve diagnostic capabilities in urban and rural health facilities, aiding disease management and response efforts.
- Rising dengue cases create demand for testing: With increasing dengue cases in regions like Guangdong, there is a pressing need for effective diagnostics, particularly in primary health clinics, to manage outbreaks effectively and protect public health.
- Growing urban population increases testing needs: As urban areas expand, the demand for vector-borne disease diagnostics is expected to rise, particularly in primary health clinics, creating opportunities for suppliers to meet this growing need.
- Investment in rapid diagnostic tests is essential: With rapid diagnostic tests accounting for 60% of malaria diagnostics, suppliers can enter the market through partnerships with healthcare facilities to meet the increasing demand for effective testing solutions.
Government Initiatives in the China Vector-Borne Disease Diagnostics Market
In 2023, the National Health Commission launched the 'Vector-Borne Disease Control Program' with a budget of 500 million yuan to improve diagnostics and surveillance. This initiative builds on the 'National Standard for Vector-Borne Disease Testing' updated in 2021, which improved accuracy and reliability in laboratories. These measures ensure that healthcare facilities are equipped with the necessary tools to effectively diagnose and manage vector-borne diseases, improving public health outcomes.
The 'Vector-Borne Disease Control Program' supports training and resources for effective diagnostics. The Chinese Center for Disease Control and Prevention initiated a nationwide training program for healthcare professionals on vector-borne disease diagnostics in 2022. This program improves the capabilities of healthcare workers, ensuring they are well-equipped to handle vector-borne disease cases effectively, ultimately benefiting patient care and public health.
Future Insight of the China Vector-Borne Disease Diagnostics Market
The China Vector-Borne Disease Diagnostics market is set for substantial changes by 2032, largely driven by the 'Healthy China 2030' initiative aimed at improving infectious disease response capabilities. The Ministry of Health's 'Vector-Borne Disease Control Program' will strengthen nationwide surveillance and diagnostics efforts. By 2025, approximately 70% of hospitals in urban areas are expected to be equipped with PCR testing capabilities, enhancing diagnostic accuracy. Increased public awareness campaigns will inform communities about vector-borne diseases, promoting proactive health measures.
Market Segmentation Analysis
Each segment group is reviewed below, with the leader by share and the fastest grower by CAGR.
By Disease Type – Malaria Dominated, Dengue Expected to Grow Fastest
According to Bhawna Singh, Assistant Manager at 6Wresearch, the largest disease type category in 2025 was Malaria, with a 46% share of total revenue. Malaria diagnostics hold the largest share due to the high incidence of over 20,000 reported cases in 2021, necessitating effective testing for timely treatment. The National Health Commission's focus on malaria highlights its critical importance in public health strategies across the country. Dengue is projected to grow fastest, at a CAGR of 8.0% during 2026–2032. Dengue is experiencing rapid growth as the Guangdong province sees a rise in cases, prompting increased testing efforts in local health facilities. This trend is further supported by the government's initiatives aimed at improving outbreak management and patient care. Suppliers should focus on enhancing their offerings for malaria diagnostics while also preparing for the growing demand for dengue testing.
By Test Type – Rapid Diagnostic Test Dominated, PCR/ELISA Expected to Grow Fastest
Rapid Diagnostic Test took a 50% share of test type in 2025, more than any other category. Rapid Diagnostic Tests dominate the market, accounting for approximately 60% of malaria diagnostics in primary health settings, making them essential for immediate patient care. Their widespread use in urban primary health clinics underscores their importance in the healthcare system. The quickest growth will come from PCR/ELISA, forecast to expand at a CAGR of 8.3% between 2026 and 2032. PCR and ELISA tests are witnessing the fastest growth as they are recognised as the gold standard for accurate detection, particularly in specialised labs. This trend is driven by the increasing need for precise diagnostics in response to rising disease cases. Buyers should consider investing in advanced PCR and ELISA testing capabilities to meet the growing demand for accurate diagnostics.
By Sample Type – Blood Dominated, Serum/Plasma Expected to Grow Fastest
Blood held a 39% share of the China Vector-Borne Disease Diagnostics Market by sample type in 2025. Blood is the primary sample type for vector-borne disease testing, widely utilised across various diagnostic methods due to its direct relevance in identifying infections. Its established role in both hospitals and clinics ensures its continued dominance in the market. Serum/Plasma is set to record the highest CAGR in this split, 7.4% over 2026–2032. Serum and plasma are gaining traction as the fastest-growing sample types, commonly used in laboratory diagnostics for their effectiveness in various testing methods. This shift indicates a broader acceptance of these samples in clinical settings, enhancing diagnostic accuracy. Suppliers must ensure their products accommodate the increasing use of serum and plasma to remain competitive in the market.
By End User – Hospitals Dominated, Primary Health Clinics Expected to Grow Fastest
In 2025, Hospitals led the end user split with a 41% share. Hospitals represent the largest share of end users, serving as critical facilities for patient management and treatment of vector-borne diseases. Their extensive infrastructure and resources allow for comprehensive diagnostic capabilities, making them indispensable in the healthcare system. Over 2026–2032, Primary Health Clinics are expected to post the fastest growth, at a CAGR of 8.5%. Primary health clinics are experiencing the fastest growth as they serve as the first point of care for patients, particularly in urban areas. The increasing emphasis on accessible healthcare drives the demand for diagnostics in these settings. Vendors should target primary health clinics with tailored solutions to capitalise on this growing segment.
Key Attractiveness of the Report
- 10 Years of Market Numbers
- Historical Data Starting from 2022 to 2025
- Base Year 2025
- Forecast Data until 2032
- Key Performance Indicators Impacting the Market
- Major Upcoming Developments and Projects
Key Highlights of the Report:
- China Vector-Borne Disease Diagnostics Market Outlook
- Market Size of China Vector-Borne Disease Diagnostics Market, 2025
- Forecast of China Vector-Borne Disease Diagnostics Market, 2032
- Historical Data and Forecast of China Vector-Borne Disease Diagnostics Revenues & Volume for the Period 2022 - 2032F
- China Vector-Borne Disease Diagnostics Market Trend Evolution
- China Vector-Borne Disease Diagnostics Market Drivers and Challenges
- China Vector-Borne Disease Diagnostics Price Trends
- China Vector-Borne Disease Diagnostics Porter's Five Forces
- China Vector-Borne Disease Diagnostics Industry Life Cycle
- Historical Data and Forecast of China Vector-Borne Disease Diagnostics Market Revenues & Volume By Disease Type for the Period 2022 - 2032F
- Historical Data and Forecast of China Vector-Borne Disease Diagnostics Market Revenues & Volume By Malaria for the Period 2022 - 2032F
- Historical Data and Forecast of China Vector-Borne Disease Diagnostics Market Revenues & Volume By Dengue for the Period 2022 - 2032F
- Historical Data and Forecast of China Vector-Borne Disease Diagnostics Market Revenues & Volume By Lyme Disease for the Period 2022 - 2032F
- Historical Data and Forecast of China Vector-Borne Disease Diagnostics Market Revenues & Volume By Chikungunya for the Period 2022 - 2032F
- Historical Data and Forecast of China Vector-Borne Disease Diagnostics Market Revenues & Volume By Test Type for the Period 2022 - 2032F
- Historical Data and Forecast of China Vector-Borne Disease Diagnostics Market Revenues & Volume By Rapid Diagnostic Test for the Period 2022 - 2032F
- Historical Data and Forecast of China Vector-Borne Disease Diagnostics Market Revenues & Volume By PCR/ELISA for the Period 2022 - 2032F
- Historical Data and Forecast of China Vector-Borne Disease Diagnostics Market Revenues & Volume By Western Blot/ELISA for the Period 2022 - 2032F
- Historical Data and Forecast of China Vector-Borne Disease Diagnostics Market Revenues & Volume By Antibody Testing for the Period 2022 - 2032F
- Historical Data and Forecast of China Vector-Borne Disease Diagnostics Market Revenues & Volume By Sample Type for the Period 2022 - 2032F
- Historical Data and Forecast of China Vector-Borne Disease Diagnostics Market Revenues & Volume By Blood for the Period 2022 - 2032F
- Historical Data and Forecast of China Vector-Borne Disease Diagnostics Market Revenues & Volume By Serum/Plasma for the Period 2022 - 2032F
- Historical Data and Forecast of China Vector-Borne Disease Diagnostics Market Revenues & Volume By Blood/CSF for the Period 2022 - 2032F
- Historical Data and Forecast of China Vector-Borne Disease Diagnostics Market Revenues & Volume By Whole Blood for the Period 2022 - 2032F
- Historical Data and Forecast of China Vector-Borne Disease Diagnostics Market Revenues & Volume By End User for the Period 2022 - 2032F
- Historical Data and Forecast of China Vector-Borne Disease Diagnostics Market Revenues & Volume By Primary Health Clinics for the Period 2022 - 2032F
- Historical Data and Forecast of China Vector-Borne Disease Diagnostics Market Revenues & Volume By Pathology Labs for the Period 2022 - 2032F
- Historical Data and Forecast of China Vector-Borne Disease Diagnostics Market Revenues & Volume By Hospitals for the Period 2022 - 2032F
- Historical Data and Forecast of China Vector-Borne Disease Diagnostics Market Revenues & Volume By Travel Clinics for the Period 2022 - 2032F
- China Vector-Borne Disease Diagnostics Import Export Trade Statistics
- Market Opportunity Assessment By Disease Type
- Market Opportunity Assessment By Test Type
- Market Opportunity Assessment By Sample Type
- Market Opportunity Assessment By End User
- China Vector-Borne Disease Diagnostics Top Companies Market Share
- China Vector-Borne Disease Diagnostics Competitive Benchmarking By Technical and Operational Parameters
- China Vector-Borne Disease Diagnostics Company Profiles
- China Vector-Borne Disease Diagnostics Key Strategic Recommendations
Market Covered
Segments analysed in this report are listed below.
By Disease Type
- Malaria
- Dengue
- Lyme Disease
- Chikungunya
By Test Type
- Rapid Diagnostic Test
- PCR/ELISA
- Western Blot/ELISA
- Antibody Testing
By Sample Type
- Blood
- Serum/Plasma
- Blood/CSF
- Whole Blood
By End User
- Primary Health Clinics
- Pathology Labs
- Hospitals
- Travel Clinics
